JLKE, Samsung Seoul Hospital Register Patent for 'Artificial Intelligence Medical Solution'

[Asia Economy Reporter Hyunseok Yoo] JLK has succeeded in filing a new patent in collaboration with Samsung Seoul Hospital.

Domestic medical artificial intelligence (AI) company JLK announced on the 3rd that it has obtained a domestic patent for the "AI-based PWI-DWI mismatch lesion extraction and integrated evaluation method and system."

The newly registered patent is the result of joint research and development through a business agreement signed in March 2019 between JLK and Professor Bang Oh-young’s team at Samsung Seoul Hospital. The product completed based on the patent is currently being applied in the field at Samsung Seoul Hospital. The company expects that it will help both medical staff and patients by rapidly expanding the market not only domestically but also overseas.

The solution named ‘JBS-06K’ patent calculates the ischemia core area and light and dark lines area by utilizing diffusion weighted image (DWI) and perfusion weighted image (PWI). This solution recommends templates according to functional or regional characteristics of the areas and provides information on whether the patient requires treatment.

Cerebral infarction, which accounts for most strokes, requires treatment to reopen blocked blood vessels as quickly as possible to prevent brain necrosis and minimize sequelae. When stroke symptoms appear, thrombolytics must be administered to the blocked vessels as soon as possible. However, the existing golden time applies a uniform treatment standard without considering individual patient circumstances, which requires administration within 4.5 hours to be effective, according to the company.

By using JLK’s JBS-06K solution, it is possible not only to predict functional loss of lesion areas extracted from artificial neural network results in diagnostic images but also to predict the expected damage range. It enables diagnosis or decision-making on the necessity of treatment suitable for each patient at a specialist level.

A JLK official said, “The analysis technology of this patent can greatly help apply the golden time according to the individual characteristics of patients with hyperacute ischemic stroke,” adding, “In the acute phase of cerebral infarction, recurrence and deterioration are frequent, and complications occur, but prognosis can be improved by using the solution.”

Samsung Seoul Hospital is leading the field of stroke MRI imaging and AI technology development. Starting with this patent, the research team of Professor Bang Oh-young of Neurology at Samsung Seoul Hospital, along with Professors Seo Woo-geun and Jung Jong-won from the same department, is conducting industry-academia joint research to implement the overall pathophysiology including infarction damage and onset time prediction, thrombosis, and collateral circulation using AI techniques.

Including this patent registration, JLK has filed and registered a total of 114 patents for core medical AI technologies domestically and internationally to date.

This content was produced with the assistance of AI translation services.